Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 29 | 2023 | 1165 | 5.090 |
Why?
|
Genital Neoplasms, Female | 10 | 2023 | 525 | 2.670 |
Why?
|
Ovarian Neoplasms | 19 | 2023 | 4856 | 2.110 |
Why?
|
Magnetic Resonance Imaging | 56 | 2023 | 35797 | 2.070 |
Why?
|
Peritoneal Neoplasms | 8 | 2022 | 689 | 2.050 |
Why?
|
Endometrial Neoplasms | 8 | 2024 | 1362 | 1.760 |
Why?
|
Uterine Diseases | 2 | 2021 | 129 | 1.330 |
Why?
|
Neoplasm Staging | 30 | 2024 | 11078 | 1.310 |
Why?
|
Radiology | 6 | 2021 | 2084 | 1.110 |
Why?
|
Carcinoma | 5 | 2023 | 2343 | 0.960 |
Why?
|
Patient Care Planning | 3 | 2016 | 905 | 0.940 |
Why?
|
Diffusion Magnetic Resonance Imaging | 9 | 2022 | 2767 | 0.890 |
Why?
|
Anal Canal | 4 | 2023 | 373 | 0.820 |
Why?
|
Incidental Findings | 3 | 2016 | 685 | 0.800 |
Why?
|
Urogenital System | 1 | 2021 | 89 | 0.770 |
Why?
|
Pancreatic Cyst | 2 | 2016 | 368 | 0.770 |
Why?
|
Pelvis | 3 | 2020 | 730 | 0.720 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2020 | 30 | 0.710 |
Why?
|
Tomography, X-Ray Computed | 22 | 2023 | 20143 | 0.710 |
Why?
|
Adenoma, Liver Cell | 1 | 2020 | 33 | 0.710 |
Why?
|
Image Interpretation, Computer-Assisted | 6 | 2016 | 3306 | 0.710 |
Why?
|
Ovary | 3 | 2022 | 961 | 0.680 |
Why?
|
Adnexal Diseases | 4 | 2022 | 102 | 0.670 |
Why?
|
Rectum | 10 | 2023 | 898 | 0.660 |
Why?
|
Teratoma | 1 | 2021 | 397 | 0.620 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2023 | 1999 | 0.600 |
Why?
|
Leiomyoma | 5 | 2022 | 690 | 0.590 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 2 | 2016 | 101 | 0.580 |
Why?
|
Pelvic Neoplasms | 1 | 2019 | 248 | 0.580 |
Why?
|
Neoadjuvant Therapy | 9 | 2023 | 2788 | 0.570 |
Why?
|
Ultrasonography | 7 | 2022 | 5901 | 0.560 |
Why?
|
Contrast Media | 12 | 2022 | 5254 | 0.560 |
Why?
|
Leiomyosarcoma | 5 | 2022 | 442 | 0.560 |
Why?
|
Mesentery | 2 | 2020 | 201 | 0.550 |
Why?
|
Aneurysm, False | 2 | 2016 | 261 | 0.530 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2023 | 1995 | 0.530 |
Why?
|
Uterus | 5 | 2021 | 664 | 0.480 |
Why?
|
Societies, Medical | 4 | 2024 | 3790 | 0.460 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 599 | 0.460 |
Why?
|
Fatty Liver | 1 | 2020 | 749 | 0.460 |
Why?
|
Benchmarking | 1 | 2020 | 1028 | 0.450 |
Why?
|
Uterine Neoplasms | 5 | 2022 | 1499 | 0.450 |
Why?
|
Vascular Neoplasms | 1 | 2015 | 170 | 0.440 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 762 | 0.440 |
Why?
|
Lymphatic Metastasis | 7 | 2023 | 2919 | 0.440 |
Why?
|
Neoplasm Invasiveness | 6 | 2023 | 3585 | 0.440 |
Why?
|
Proctoscopy | 1 | 2012 | 41 | 0.430 |
Why?
|
Humans | 104 | 2024 | 746630 | 0.410 |
Why?
|
Female | 70 | 2024 | 382450 | 0.400 |
Why?
|
Tumor Burden | 6 | 2019 | 1882 | 0.400 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1376 | 0.390 |
Why?
|
Femoral Artery | 1 | 2016 | 833 | 0.390 |
Why?
|
Adrenal Glands | 2 | 2011 | 556 | 0.380 |
Why?
|
Gadolinium DTPA | 1 | 2014 | 824 | 0.360 |
Why?
|
Positron-Emission Tomography | 5 | 2023 | 6419 | 0.360 |
Why?
|
Anus Neoplasms | 3 | 2023 | 327 | 0.360 |
Why?
|
Peliosis Hepatis | 1 | 2009 | 1 | 0.360 |
Why?
|
Image Enhancement | 2 | 2018 | 2871 | 0.350 |
Why?
|
Shock, Septic | 3 | 2012 | 765 | 0.350 |
Why?
|
Diagnostic Imaging | 3 | 2019 | 3494 | 0.340 |
Why?
|
Consensus | 5 | 2023 | 3017 | 0.340 |
Why?
|
Medical Oncology | 1 | 2021 | 2269 | 0.340 |
Why?
|
Retrospective Studies | 29 | 2023 | 78313 | 0.310 |
Why?
|
Patient Selection | 3 | 2017 | 4194 | 0.310 |
Why?
|
Hepatic Artery | 3 | 2014 | 230 | 0.310 |
Why?
|
Radiopharmaceuticals | 5 | 2023 | 2655 | 0.300 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2020 | 2258 | 0.290 |
Why?
|
Clinical Protocols | 1 | 2013 | 1428 | 0.290 |
Why?
|
Prognosis | 12 | 2023 | 29079 | 0.290 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 2007 | 91 | 0.290 |
Why?
|
Aged | 36 | 2023 | 164383 | 0.260 |
Why?
|
Diaphragm | 2 | 2020 | 350 | 0.260 |
Why?
|
Imaging, Three-Dimensional | 4 | 2020 | 4011 | 0.260 |
Why?
|
Sensitivity and Specificity | 7 | 2020 | 14543 | 0.260 |
Why?
|
Liver Transplantation | 5 | 2014 | 2203 | 0.250 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2019 | 462 | 0.250 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4254 | 0.240 |
Why?
|
Diagnosis, Differential | 7 | 2020 | 12840 | 0.240 |
Why?
|
Reproducibility of Results | 9 | 2022 | 19819 | 0.240 |
Why?
|
Pancreatic Neoplasms | 3 | 2023 | 5260 | 0.240 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 2033 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9193 | 0.220 |
Why?
|
Middle Aged | 37 | 2021 | 214618 | 0.220 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2021 | 8902 | 0.220 |
Why?
|
Laparoscopy | 3 | 2022 | 2149 | 0.210 |
Why?
|
Aged, 80 and over | 15 | 2021 | 57586 | 0.210 |
Why?
|
Knee Joint | 1 | 2011 | 1648 | 0.200 |
Why?
|
Granulosa Cell Tumor | 1 | 2022 | 72 | 0.200 |
Why?
|
Dermoid Cyst | 1 | 2022 | 92 | 0.200 |
Why?
|
Disease-Free Survival | 4 | 2022 | 6789 | 0.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11584 | 0.190 |
Why?
|
Adult | 29 | 2021 | 215192 | 0.190 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 4272 | 0.190 |
Why?
|
Krukenberg Tumor | 1 | 2020 | 13 | 0.180 |
Why?
|
Biopsy | 3 | 2019 | 6734 | 0.180 |
Why?
|
Pseudomyxoma Peritonei | 1 | 2020 | 22 | 0.180 |
Why?
|
Urogenital Neoplasms | 1 | 2021 | 135 | 0.180 |
Why?
|
Sigmoid Neoplasms | 1 | 2019 | 52 | 0.170 |
Why?
|
Europe | 3 | 2024 | 3355 | 0.160 |
Why?
|
Algorithms | 6 | 2023 | 13810 | 0.160 |
Why?
|
Biology | 1 | 2020 | 289 | 0.150 |
Why?
|
Omentum | 2 | 2020 | 173 | 0.150 |
Why?
|
Carcinoma, Endometrioid | 1 | 2020 | 275 | 0.150 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2372 | 0.150 |
Why?
|
Leucovorin | 1 | 2019 | 623 | 0.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 198 | 0.150 |
Why?
|
Iohexol | 1 | 2018 | 196 | 0.140 |
Why?
|
Cysts | 1 | 2022 | 675 | 0.140 |
Why?
|
Urogenital Abnormalities | 1 | 2020 | 256 | 0.140 |
Why?
|
Radiography, Abdominal | 1 | 2020 | 533 | 0.140 |
Why?
|
Sex Reassignment Surgery | 1 | 2019 | 151 | 0.140 |
Why?
|
Placenta Accreta | 1 | 2020 | 237 | 0.130 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 416 | 0.130 |
Why?
|
Pelvic Exenteration | 1 | 2015 | 21 | 0.130 |
Why?
|
Elasticity Imaging Techniques | 1 | 2020 | 383 | 0.120 |
Why?
|
Prostatic Neoplasms | 2 | 2017 | 11215 | 0.120 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 2014 | 47 | 0.120 |
Why?
|
Muscles | 1 | 2020 | 1583 | 0.120 |
Why?
|
Central Nervous System Fungal Infections | 1 | 2014 | 25 | 0.120 |
Why?
|
Fluorouracil | 1 | 2019 | 1603 | 0.120 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2229 | 0.120 |
Why?
|
Neoplasms | 2 | 2024 | 21715 | 0.120 |
Why?
|
Extremities | 1 | 2020 | 850 | 0.120 |
Why?
|
Endometrium | 1 | 2017 | 423 | 0.120 |
Why?
|
Myometrium | 1 | 2015 | 177 | 0.120 |
Why?
|
Gastric Fistula | 1 | 2015 | 72 | 0.120 |
Why?
|
Gastrointestinal Transit | 1 | 2015 | 95 | 0.120 |
Why?
|
Male | 24 | 2021 | 351420 | 0.110 |
Why?
|
Young Adult | 9 | 2021 | 57163 | 0.110 |
Why?
|
Gastroplasty | 1 | 2015 | 152 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2019 | 554 | 0.110 |
Why?
|
Treatment Outcome | 12 | 2023 | 63732 | 0.110 |
Why?
|
Gadolinium | 1 | 2018 | 945 | 0.110 |
Why?
|
Neoplasm Seeding | 1 | 2012 | 86 | 0.100 |
Why?
|
Aspergillosis | 1 | 2014 | 244 | 0.100 |
Why?
|
Terminology as Topic | 1 | 2019 | 1530 | 0.100 |
Why?
|
Motion | 1 | 2016 | 781 | 0.100 |
Why?
|
Vascular Grafting | 1 | 2013 | 150 | 0.100 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2012 | 127 | 0.100 |
Why?
|
Statistics, Nonparametric | 2 | 2020 | 2846 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4883 | 0.100 |
Why?
|
Muscular Atrophy | 1 | 2014 | 328 | 0.090 |
Why?
|
Precancerous Conditions | 1 | 2018 | 971 | 0.090 |
Why?
|
Placenta | 1 | 2020 | 1682 | 0.090 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 15010 | 0.090 |
Why?
|
Fluoroscopy | 1 | 2015 | 939 | 0.090 |
Why?
|
Etomidate | 1 | 2012 | 188 | 0.090 |
Why?
|
Posterior Cruciate Ligament | 1 | 2011 | 86 | 0.090 |
Why?
|
Saphenous Vein | 1 | 2013 | 523 | 0.090 |
Why?
|
Densitometry | 1 | 2010 | 152 | 0.090 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2014 | 460 | 0.090 |
Why?
|
Patient Care | 1 | 2015 | 621 | 0.090 |
Why?
|
Phenotype | 2 | 2018 | 16261 | 0.090 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 3837 | 0.090 |
Why?
|
Antifungal Agents | 1 | 2014 | 708 | 0.090 |
Why?
|
Pancreas | 1 | 2016 | 1674 | 0.090 |
Why?
|
ROC Curve | 2 | 2020 | 3497 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2017 | 2145 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3478 | 0.080 |
Why?
|
Radiotherapy | 1 | 2016 | 1505 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13586 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2021 | 38771 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2012 | 547 | 0.080 |
Why?
|
Critical Illness | 3 | 2020 | 2693 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2016 | 6463 | 0.080 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8521 | 0.070 |
Why?
|
Automation | 1 | 2010 | 581 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1959 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2023 | 3985 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2012 | 847 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 1002 | 0.070 |
Why?
|
Anterior Cruciate Ligament | 1 | 2011 | 422 | 0.070 |
Why?
|
Models, Statistical | 1 | 2021 | 5031 | 0.070 |
Why?
|
Mutation | 4 | 2020 | 29627 | 0.070 |
Why?
|
Proteomics | 1 | 2020 | 3709 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2246 | 0.070 |
Why?
|
Postoperative Complications | 3 | 2019 | 15356 | 0.070 |
Why?
|
Interferon-gamma | 1 | 2014 | 3143 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3429 | 0.060 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2016 | 1672 | 0.060 |
Why?
|
Kidney | 2 | 2020 | 6990 | 0.060 |
Why?
|
Surgical Flaps | 1 | 2014 | 1657 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4536 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2012 | 1160 | 0.060 |
Why?
|
Hydrocortisone | 1 | 2012 | 1792 | 0.060 |
Why?
|
Intubation, Intratracheal | 1 | 2012 | 1355 | 0.060 |
Why?
|
Fasting | 2 | 2020 | 1577 | 0.060 |
Why?
|
Cartilage, Articular | 1 | 2011 | 1086 | 0.060 |
Why?
|
Preoperative Care | 1 | 2012 | 2220 | 0.050 |
Why?
|
Sepsis | 2 | 2014 | 2590 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5695 | 0.050 |
Why?
|
Pilot Projects | 2 | 2020 | 8378 | 0.050 |
Why?
|
Pregnancy | 5 | 2023 | 29297 | 0.050 |
Why?
|
Fascia | 1 | 2023 | 141 | 0.050 |
Why?
|
Prospective Studies | 4 | 2020 | 53253 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3545 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7280 | 0.050 |
Why?
|
Adnexa Uteri | 1 | 2022 | 43 | 0.050 |
Why?
|
Software | 2 | 2017 | 4400 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2017 | 3173 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4057 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2023 | 627 | 0.050 |
Why?
|
Hysterosalpingography | 1 | 2020 | 29 | 0.050 |
Why?
|
Glucose-6-Phosphate Isomerase | 1 | 2020 | 51 | 0.050 |
Why?
|
Abdominal Cavity | 1 | 2020 | 35 | 0.040 |
Why?
|
DNA Polymerase II | 1 | 2020 | 104 | 0.040 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2020 | 63 | 0.040 |
Why?
|
Parasympatholytics | 1 | 2020 | 91 | 0.040 |
Why?
|
Anastomosis, Surgical | 2 | 2014 | 968 | 0.040 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2020 | 89 | 0.040 |
Why?
|
Intensive Care Units | 4 | 2014 | 3674 | 0.040 |
Why?
|
Risk Assessment | 3 | 2022 | 23464 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 849 | 0.040 |
Why?
|
Adolescent | 5 | 2019 | 86278 | 0.040 |
Why?
|
Radiology Information Systems | 1 | 2024 | 524 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2023 | 635 | 0.040 |
Why?
|
France | 1 | 2020 | 500 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1679 | 0.040 |
Why?
|
Hand | 1 | 2023 | 877 | 0.040 |
Why?
|
Glucagon | 1 | 2020 | 508 | 0.040 |
Why?
|
Hospitals, University | 1 | 2020 | 567 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2020 | 427 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12280 | 0.040 |
Why?
|
Ureter | 1 | 2020 | 375 | 0.040 |
Why?
|
Melanoma | 1 | 2016 | 5574 | 0.040 |
Why?
|
Injections | 1 | 2020 | 830 | 0.040 |
Why?
|
Documentation | 1 | 2023 | 876 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17445 | 0.040 |
Why?
|
Cicatrix | 1 | 2022 | 769 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2020 | 697 | 0.040 |
Why?
|
Hysterectomy | 1 | 2022 | 915 | 0.030 |
Why?
|
Menstrual Cycle | 1 | 2020 | 535 | 0.030 |
Why?
|
Cyclin E | 1 | 2017 | 158 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2012 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2020 | 583 | 0.030 |
Why?
|
Nephrons | 1 | 2017 | 207 | 0.030 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 255 | 0.030 |
Why?
|
Patient Positioning | 1 | 2018 | 322 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2020 | 498 | 0.030 |
Why?
|
Vagina | 1 | 2020 | 806 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 551 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2017 | 330 | 0.030 |
Why?
|
Brain | 1 | 2021 | 26597 | 0.030 |
Why?
|
Transportation of Patients | 1 | 2014 | 174 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2020 | 1168 | 0.030 |
Why?
|
Anastomotic Leak | 1 | 2015 | 157 | 0.030 |
Why?
|
Spine | 1 | 2020 | 1098 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2017 | 725 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2010 | 21693 | 0.030 |
Why?
|
Gene Amplification | 1 | 2017 | 1083 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 1179 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1975 | 0.030 |
Why?
|
Postoperative Period | 1 | 2017 | 1811 | 0.020 |
Why?
|
Endometriosis | 1 | 2020 | 872 | 0.020 |
Why?
|
Artifacts | 1 | 2020 | 1873 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2021 | 3743 | 0.020 |
Why?
|
Nephrectomy | 1 | 2017 | 1031 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13218 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3695 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2023 | 3413 | 0.020 |
Why?
|
Liver Failure | 1 | 2012 | 248 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2887 | 0.020 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 523 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2019 | 1854 | 0.020 |
Why?
|
Observer Variation | 1 | 2015 | 2574 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2885 | 0.020 |
Why?
|
Radiography | 1 | 2020 | 6950 | 0.020 |
Why?
|
Community-Acquired Infections | 1 | 2012 | 445 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2012 | 868 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3611 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6148 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10096 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2016 | 5096 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2015 | 1950 | 0.020 |
Why?
|
Propensity Score | 1 | 2012 | 1848 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7236 | 0.020 |
Why?
|
Time Factors | 2 | 2019 | 39622 | 0.020 |
Why?
|
Internet | 1 | 2017 | 3039 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12021 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9320 | 0.010 |
Why?
|
Reoperation | 1 | 2013 | 4218 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13170 | 0.010 |
Why?
|
Regression Analysis | 1 | 2011 | 6334 | 0.010 |
Why?
|
Risk Factors | 2 | 2019 | 72447 | 0.010 |
Why?
|
Length of Stay | 1 | 2012 | 6293 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 40534 | 0.010 |
Why?
|
Liver | 1 | 2013 | 7382 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15555 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7229 | 0.010 |
Why?
|
United States | 1 | 2022 | 70437 | 0.010 |
Why?
|